Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de estudo
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Neurosci Res ; 55(4): 397-402, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16766071

RESUMO

The excitotoxicity induced by QA has been related to its ability to increase free radical content and oxidative stress. In order to investigate the time course of toxicity and oxidative profile in the mice hippocampus following seizures induced by QA infusion (36.8 nM, i.c.v.), we evaluated the cellular damage (PI uptake assay), content of ROS formation (DCF assay) and the total radical antioxidant potential (TRAP) and reactivity (TAR) levels. The present results showed that a cellular damage occurred as early as 4 h after QA infusion coincident with an increase in the ROS contents, which returned to control levels after 24 h, while the cellular damage persisted for 72 h. There was a marked increased in the total antioxidant capacity at 8 h after QA infusion in both reactivity and potential levels. By 72 h post-treatment, the TRAP levels decreased, but the TAR levels remained augmented. Therefore, the delayed and persistent increase in the antioxidant capacity after QA insult may be a cellular adaptative response, probably contributing to decrease the ROS levels in order to prevent the spreading of the cellular damage. Therefore, the increase in the QA level in the brain ventricle may induce oxidative stress, which is followed by a persistent response in the antioxidant system in the hippocampus. The present study may, therefore, contribute to elucidate the mechanism of the brain dysfunction in patients with several neurological disorders involving elevation of QA in the CSF.


Assuntos
Encefalite/metabolismo , Hipocampo/metabolismo , Doenças Neurodegenerativas/metabolismo , Estresse Oxidativo/fisiologia , Ácido Quinolínico/efeitos adversos , Complexo AIDS Demência/complicações , Complexo AIDS Demência/metabolismo , Complexo AIDS Demência/fisiopatologia , Animais , Antioxidantes/metabolismo , Células Cultivadas , Modelos Animais de Doenças , Encefalite/induzido quimicamente , Encefalite/fisiopatologia , Radicais Livres/metabolismo , Hipocampo/efeitos dos fármacos , Hipocampo/fisiopatologia , Injeções Intraventriculares , Masculino , Camundongos , Degeneração Neural/induzido quimicamente , Degeneração Neural/metabolismo , Degeneração Neural/fisiopatologia , Doenças Neurodegenerativas/induzido quimicamente , Doenças Neurodegenerativas/fisiopatologia , Estresse Oxidativo/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo , Convulsões/etiologia , Convulsões/metabolismo , Convulsões/fisiopatologia , Fatores de Tempo , Regulação para Cima/fisiologia
2.
Neurosci Res ; 53(1): 77-83, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16011854

RESUMO

The excitatory amino acids (EAAs) transporters regulate the balance between physiological and pathological signaling over stimulation of the glutamatergic system pathway. The effect of transportable substrates and glutamate (Glu) receptor agonists on Glu uptake in neuronal cells was assessed at different conditions. Cells pre-incubated with Glu, L- or D-aspartate (Asp) and washed presented an inhibition on [(3)H]-Glu uptake and this effect was not mimicked by Glu receptors agonists. The effects of L- and D-Asp were not altered by the presence of N-methyl-d-aspartate (NMDA) receptor antagonists. Thus, the reduction on Glu uptake induced by EAAs is probably linked to the transporter activity. In contrast, the presence of NMDA or (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (SR-ACPD) during the pre-incubation and the [(3)H]-Glu uptake assay period increased Glu uptake, whilst kainic acid (KA) had no effect. The NMDA effect was not altered by its antagonists (+/-)-2-amino-5-phosphonopentanoic acid (AP-5) or dizocilpine (MK-801). The SR-ACPD effect was due to the activation of metabotropic Glu receptor, since it was abolished by its antagonist, L(+/-)-2-amino-3-phosphonopropionic acid (L-AP3). Thus, the current studies suggest that the neuronal EAAs transporter is regulated in different manner by transportable substrates and Glu receptor agonists. The possible involvement of this modulation after certain neurotoxicity insults is discussed.


Assuntos
Sistema X-AG de Transporte de Aminoácidos/metabolismo , Agonistas de Aminoácidos Excitatórios/farmacologia , Neurônios/efeitos dos fármacos , Receptores de Glutamato/metabolismo , Sistema X-AG de Transporte de Aminoácidos/agonistas , Animais , Animais Recém-Nascidos , Ácido Aspártico/farmacologia , Células Cultivadas , Cerebelo/citologia , Cicloleucina/análogos & derivados , Cicloleucina/farmacologia , Maleato de Dizocilpina/farmacologia , Relação Dose-Resposta a Droga , Interações Medicamentosas , Antagonistas de Aminoácidos Excitatórios/farmacologia , Ligantes , N-Metilaspartato/farmacologia , Naftalenos , Neurônios/metabolismo , Fármacos Neuroprotetores/farmacologia , Oxepinas , Ratos , Ratos Wistar , Trítio/metabolismo , Valina/análogos & derivados , Valina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA